These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27766728)

  • 1. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
    Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
    Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
    Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
    Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
    Suzuki S; Oura T; Takeuchi M; Boye KS
    Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):131-138. PubMed ID: 31189509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
    Boye KS; Mody R; Wu J; Lage MJ; Botros FT; Woodward B
    Clin Ther; 2018 Aug; 40(8):1396-1407. PubMed ID: 30093131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
    Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
    J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
    Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
    Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.
    Inagaki N; Araki E; Oura T; Matsui A; Takeuchi M; Tanizawa Y
    Diabetes Obes Metab; 2016 Dec; 18(12):1279-1282. PubMed ID: 27488246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
    Kaneko S; Oura T; Matsui A; Shingaki T; Takeuchi M
    Endocr J; 2017 Dec; 64(12):1165-1172. PubMed ID: 28904247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
    Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
    Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
    Wang W; Yan X; Cheng Z; Zhang Q; Wang R; Deng Y; Ma J; Zhu D
    Diabetes Obes Metab; 2023 Dec; 25(12):3690-3699. PubMed ID: 37732487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).
    Tuttle KR; Lakshmanan MC; Rayner B; Zimmermann AG; Woodward B; Botros FT
    Diabetes Obes Metab; 2019 Jun; 21(6):1493-1497. PubMed ID: 30762290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
    Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
    Yu M; Van Brunt K; Varnado OJ; Boye KS
    Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.